Faecal incontinence Signs and Symptoms Faecal incontinence
Conditions
Interventions
Application of topical estriol (Ovestin®) or placebo according to the randomisation. The cream was applied in the anal canal mucosa three times a day (tid) during six weeks. Dosage approximately 1 g e
Sponsors
Pontifical Catholic University of Chile (Pontificia Universidad Catolica de Chile) (Chile)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Post-menopausal women (at least 1 year) without hormonal substitution 2. Aged 69 years ± 8 (treatment group) and 66 years ± 8 (placebo group) 3. Wexner's faecal incontinence (FI) score greater than 5 4. Anal ultrasound with less than 50% damage to external sphincter 5. Accepted informed consent
Exclusion criteria
Exclusion criteria: 1. Perianal lesions 2. History of endometrial, breast or cervix cancer 3. Allergy to oestrogens
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The degree of continence was evaluated by Wexner's FI score at the beginning and end of the protocol (six weeks since the beginning). | — |
Secondary
| Measure | Time frame |
|---|---|
| In order to evaluate the degree of impact on quality of life, we used a quality of life questionnaire validated and accepted for the Spanish language (ECIF), at the beginning and end of the protocol (six weeks since the beginning). | — |
Countries
Chile
Outcome results
None listed